Ireland’s largest growth capital investor—BGF—has completed a €6 million equity investment in Vasorum Limited.
Vasorum is a Dublin based business specialising in devices used to close arterial punctures in vascular, cardiology, radiology and neuroradiology procedures. Based in Dublin, the company is led by founder and CEO, Jim Coleman, and former CR Bard senior executive, Chas Taylor.
BGF invests in minority positions in growing businesses and aims to support and facilitate the growth plans of founders and owners. BGF in Ireland is supported by the Ireland Strategic Investment Fund (ISIF) and the main Irish banks.
Vasorum developed and markets the Celt arterial closure device (ACD), which is used to close femoral artery punctures. The Celt ACD is a Class III medical device based on a patented platform technology, which was approved by the US Food and Drug Administration (FDA) in 2017, and has been used in over 70,000 patients to date. BGF’s investment will be used to accelerate the commercial roll-out of Celt ACD in the USA and to invest in new product development.
